Cart
sales@molnova.com
DRI-C21045
CAS No. 2101765-81-3
DRI-C21045( —— )
Catalog No. M26176 CAS No. 2101765-81-3
Dri-c21045 showed concentration-dependent inhibition of NF-kB activation and all CD40L induced by B cell proliferation with IC50 of 17.1 μM and 4.5 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 41 | In Stock |
|
| 10MG | 69 | In Stock |
|
| 25MG | 132 | In Stock |
|
| 50MG | 231 | In Stock |
|
| 100MG | 345 | In Stock |
|
| 200MG | 490 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDRI-C21045
-
NoteResearch use only, not for human use.
-
Brief DescriptionDri-c21045 showed concentration-dependent inhibition of NF-kB activation and all CD40L induced by B cell proliferation with IC50 of 17.1 μM and 4.5 μM.
-
DescriptionDri-c21045 showed concentration-dependent inhibition of NF-kB activation and all CD40L induced by B cell proliferation with IC50 of 17.1 μM and 4.5 μM, respectively. Dri-c21045 is an effective selective inhibitor of CD40-CD40L synergistic stimulator protein-protein interaction (PPI) with IC50 of 0.17 μM.
-
In VitroDRI-C21045 (3.2-100 μM; 18 h) concentration-dependently inhibits the CD40L-induced NF-κB activation in CD40 sensor cells.DRI-C21045 (0.6-50 μM; 48 h) blocks CD40L-induced functional activation of primary B cells.DRI-C21045 (0.4-50 μM; 48 h) inhibits CD40L-induced MHC-II upregulation in THP-1 cells.DRI-C21045 (2-100 μM; 48 h) inhibits CD40L-induced B cell proliferation.DRI-C21045 shows no signs of cytotoxicity for concentrations of up to 100 and 200 μM and has no genotoxic potential for concentrations of up to 500 μM.
-
In VivoDRI-C21045 (30 mg/kg; daily, s.c.; in 20% HPβCD) prolongs graft survival in a murine allogeneic skin transplant model.DRI-C21045 (20-60 mg/kg; twice daily s.c.; in 20% HPβCD) inhibits alloantigen-induced T cell expansion in the draining lymph nodes (DLNs). Animal Model:Full-thickness ear skins from BALB/c were transplanted onto the dorsal thorax of C57BL/6 Dosage:30 mg/kg Administration:Daily s.c; administered in 20% w/v hydroxypropyl-β-cyclodextrin (HPβCD) solutionResult:Caused prolongation of skin allograft survival.
-
Synonyms——
-
PathwayApoptosis
-
TargetNF-κB
-
Recptoranandamide cellular uptake
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2101765-81-3
-
Formula Weight580.61
-
Molecular FormulaC32H24N2O7S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 2 mg/mL (3.44 mM)
-
SMILESCOC(=O)c1ccc(cc1)C(=O)Nc1ccc(cc1)-c1ccc(cc1)C(=O)Nc1cccc2cccc(c12)S(O)(=O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ortar G, et al. Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem Pharmacol. 2003 May 1;65(9):1473-81.
molnova catalog
related products
-
Scopolin
Scopolin can reduce the clinical symptoms of rat AIA by inhibiting inflammation and angiogenesis, and this compound may be a potent agent for angiogenesis related diseases and can serve as a structural base for screening more potent synthetic analogs.
-
(R)-(-)-Ibuprofen
An enantiomer of Ibuprofen that is generally not considered a COX inhibitor and is instead thought to be involved in pathways of lipid metabolism as it is incorporated into triglycerides along with fatty acids.
-
B022
B022 is a selective and potent NF-κB-induced kinase (NIK) inhibitor (Ki: 4.2 nM) and a chemical probe for treating liver inflammation and injury, protecting the liver from inflammation and injury caused by oxidative stress and toxins.
